Episode 64: Mycobacterium tuberculosis: the forgotten pandemic

The microbinfie podcast explores the complex world of Mycobacterium tuberculosis (MTB), revealing the ongoing global health challenge of tuberculosis and its intricate genomic and epidemiological characteristics.

Welcome back to our series where we explore specific microbial species in detail. Today, we're focusing on Mycobacterium tuberculosis, often referred to as the "forgotten pandemic." Our distinguished guests for this discussion are:

• Dr. Suzie Hingley-Wilson, Lecturer in Bacteriology at the University of Surrey
• Dr. Dany Beste, Senior Lecturer in Microbial Metabolism at the University of Surrey
• Dr. Conor Meehan, Assistant Professor in Molecular Microbiology at the University of Bradford

Key Points

1. Global TB Epidemiology

• TB remains a leading cause of infectious death, with approximately 10 million cases annually
• About 1.5 million deaths occur each year, with 500-600,000 cases being drug-resistant
• COVID-19 pandemic has significantly impacted TB diagnosis and treatment

2. Vaccine and Treatment Challenges

• BCG vaccine effectiveness varies globally, with protection ranging from less than 5% to lifelong immunity
• Treatment typically requires four drugs over six months, with challenges in patient adherence
• Recent clinical trials show promising developments in reducing treatment duration

3. Genomic Complexity

• MTB has a low mutation rate (10^-6 to 10^-7)
• Intra-host variation and mixed infections are increasingly recognized
• No significant genomic recombination observed in classic MTB strains

Take-Home Messages

• TB remains a critical global health challenge, particularly in developing countries
• Genomic research is revealing the complex nature of MTB infection and transmission
• Continued research is crucial for developing more effective treatments and vaccines